对乙酰氨基酚急性过量肝毒性预测:psi参数与浓度氨基转移酶活性乘积联合检测提高敏感性
本研究为2007年1月至2016年12月对乙酰氨基酚急性过量患者的回顾性分析,共纳入421例,其中肝毒性发生率为13.5%(57例)。研究评估了psi参数(mmol/L×h)与对乙酰氨基酚浓度氨基转移酶活性乘积(g U/L²)之和的预测价值,其ROC曲线下面积为0.989(95% CI: 0.974-0.997),最佳切点9.723,敏感度96.5%、特异度97.3%。该联合指标ROC曲线下面积优于单独psi参数(0.916;95% CI: 0.885-0.941)和单独浓度氨基转移酶活性乘积(0.901;95% CI: 0.868-0.928)。作者认为将其纳入临床方案可能改善对乙酰氨基酚过量的管理。
要点
- 对乙酰氨基酚急性过量患者中,psi参数与浓度氨基转移酶活性乘积之和的ROC曲线下面积为0.989(95% CI: 0.974-0.997),最佳切点9.723,敏感度96.5%、特异度97.3%。
- 该联合指标ROC曲线下面积优于单独psi参数(0.916;95% CI: 0.885-0.941)和单独浓度氨基转移酶活性乘积(0.901;95% CI: 0.868-0.928)。
- 研究纳入421例急性对乙酰氨基酚过量患者,肝毒性(AST或ALT≥1,000 U/L)发生率为13.5%(57例)。
- 作者认为将联合指标纳入临床方案可能通过精确识别肝毒性高风险个体来改善对乙酰氨基酚过量的管理。
适用人群与场景
- 急性对乙酰氨基酚过量患者,来自2007年1月至2016年12月的回顾性分析,共421例,多为女性(82.9%),中位年龄23岁。
诊断标准与关键阈值
- 肝毒性定义为天冬氨酸氨基转移酶或丙氨酸氨基转移酶活性≥1,000 U/L。
- 联合指标(psi参数与浓度氨基转移酶活性乘积之和)最佳切点为9.723,采用最大约登指数法确定。
研究设计与关键结果
- 研究类型为回顾性分析,纳入421例急性对乙酰氨基酚过量患者,肝毒性发生率为13.5%(57例)。
- 联合指标(psi参数+浓度氨基转移酶活性乘积)的ROC曲线下面积为0.989(95% CI: 0.974-0.997),最佳切点9.723,敏感度96.5%、特异度97.3%。
- 单独psi参数的ROC曲线下面积为0.916(95% CI: 0.885-0.941);单独浓度氨基转移酶活性乘积的ROC曲线下面积为0.901(95% CI: 0.868-0.928)。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,将psi参数与浓度氨基转移酶活性乘积之和纳入临床方案,可能通过精确识别肝毒性高风险个体来改善对乙酰氨基酚过量的管理,从而便于个体化治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: While factors like high serum paracetamol (acetaminophen) concentration and delayed acetylcysteine treatment increase hepatotoxicity risk, existing predictive tools, such as the paracetamol concentration aminotransferase activity multiplication product and the psi (ψ) parameter, lack definitive accuracy. This study evaluated the paracetamol psi parameter multiplication product addition against the psi parameter and the paracetamol concentration aminotransferase activity multiplication product for predicting hepatotoxicity following an acute paracetamol overdose.
METHODS: A retrospective analysis of patients with acute paracetamol overdose from January 2007 to December 2016 was conducted. The paracetamol psi parameter multiplication product addition, calculated by summing the psi parameter (mmol/L × h) and the paracetamol concentration aminotransferase activity multiplication product (g U/L2), was used. Hepatotoxicity was defined as aspartate or alanine aminotransferase activities ≥1,000 U/L. Diagnostic accuracy was assessed through sensitivity, specificity, the area under the receiver operating characteristic curve, and their corresponding 95% CI, with the optimal cutoff determined using the maximum Youden index method.
RESULTS: The study comprised 421 patients, mostly female (82.9%) with a median age of 23 years. Hepatotoxicity occurred in 13.5% (57 patients). The paracetamol psi parameter multiplication product addition showed an area under the receiver operating characteristic curve of 0.989 (95% CI: 0.974-0.997), with an optimal cutoff at 9.723, providing 96.5% sensitivity and 97.3% specificity. The paracetamol psi parameter multiplication product addition demonstrated superior performance in area under the receiver operating characteristic curve compared to the individual assessments of the psi parameter (0.916; 95% CI: 0.885-0.941) and the paracetamol concentration aminotransferase activity multiplication product (0.901; 95% CI: 0.868-0.928).
DISCUSSION: The paracetamol psi parameter multiplication product addition appears to be a more effective diagnostic tool than the psi parameter or the paracetamol concentration aminotransferase activity multiplication product alone.
CONCLUSION: Incorporating the paracetamol psi parameter multiplication product addition into clinical protocols could improve paracetamol overdose management by enabling precise identification of individuals at heightened risk for hepatotoxicity, thereby facilitating the customization of treatment approaches.
参考来源
- Chomchai S, Mekavuthikul P, Phuditshinnapatra J, et al. Augmenting the sensitivity for hepatotoxicity prediction in acute paracetamol overdose: combining psi (ψ) parameter and paracetamol concentration aminotransferase activity multiplication product. Clin Toxicol (Phila). 2024. PMID: 39494725. doi:10.1080/15563650.2024.2412208
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。